Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neuren Pharmaceuticals Ltd.
Headquarters: Camberwell, VIC, Australia
Website: http://www.neurenpharma.com
Year Founded: 2004
Status: Public
Industry Sector: HealthTechnology
CEO: Jon Pilcher
Number Of Employees: N/A
Enterprise Value: $877,854,668
PE Ratio: 8.87
Exchange/Ticker 1: ASX:NEU
Exchange/Ticker 2: Pink:NURPF
Latest Market Cap: $777,942,975
BioCentury | Nov 12, 2024
Deals
GHO, Ampersand to take Avid Bioservices private
BioCentury’s Deals report also includes Karalis’s public path via AlloVir reverse merger, and updates from Oblenio-Leads, Daiichi-Alteogen and Acadia
BioCentury | Nov 6, 2024
Deals
With doubts about voucher program extension, Acadia strikes $150M sale
The deal, among the biggest in years for a priority review voucher, comes weeks after a continuing resolution kept the program alive until December
BioCentury | Jul 14, 2023
Finance
July 13 Quick Takes: Apogee prices $300M IPO
Plus: New funds for BGV, Modi; Arix reviewing alternatives; and updates from Bicycle, Roche, Causaly, Neuren-Acadia
BioCentury | Mar 2, 2023
Data Byte
At least nine PDUFA dates on deck in March
Decisions include leniolisib and trofinetide, both of which could be the first drugs approved for their indications
BioCentury | Sep 13, 2022
Finance
Sept. 12 Quick Takes: Nimbus draws $125M to advance pair of lead molecules
Plus new name, COVID-19 mAb for Adagio and updates from Horizon, Acadia, Chiesi and more
BioCentury | Mar 14, 2016
Emerging Company Profile
AMO's CNS ammunition
AMO is repurposing compounds to treat CNS deficits in fragile X and DM1
BioCentury | Aug 20, 2012
Emerging Company Profile
Mind-NRG: New neuroprotection
Mind-NRG's neuregulin 1 fragment could treat early stage Parkinson's disease
Items per page:
1 - 10 of 40